Ratings Arcellx, Inc.

Equities

ACLX

US03940C1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
53.62 ^USD	+1.57%		+1.69%	-3.39%

May. 15	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating	MT
May. 14	Evercore ISI Starts Arcellx With Outperform Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ARCELLX, INC.	-3.39%	2.82B	-
MODERNA, INC.	+33.63%	50.85B	B-
IQVIA HOLDINGS INC.	-0.09%	42.82B	B
LONZA GROUP AG	+49.62%	42.03B	A
CELLTRION, INC.	-4.96%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B	B
BIO-TECHNE CORPORATION	+8.61%	13.05B	B+
MEDPACE HOLDINGS, INC.	+28.31%	12.16B	C+
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes